Estee Lauder Companies Inc (NYSE:EL). reported its Q2 Fiscal 2025 earnings, revealing a stronger-than-expected performance with an adjusted earnings per share (EPS) of $0.62, significantly surpassing ...
OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today provided a corporate update to the marketplace to ...